Search

Your search keyword '"Guédès, Antoine"' showing total 2 results
Start Over Author "Guédès, Antoine" Journal atherosclerosis
2 results on '"Guédès, Antoine"'

1. Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: Results of the MEDCOR trial

Author

Barbato, Emanuele, primary, Herman, Arnold, additional, Benit, Edouard, additional, Janssens, Luc, additional, Lalmand, Jacques, additional, Hoffer, Etienne, additional, Chenu, Patrick, additional, Guédès, Antoine, additional, Missault, Luc, additional, Pirenne, Bruno, additional, Cardinal, François, additional, Vercauteren, Steven, additional, and Wijns, William, additional

Published
2015
Full Text
View/download PDF

2. Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: Results of the MEDCOR trial

Author

Antoine Guedes, Arnold G. Herman, Bruno Pirenne, Emanuele Barbato, Luc Janssens, Edouard Benit, Patrick Chenu, William Wijns, François Cardinal, Etienne Hoffer, Luc Missault, Jacques Lalmand, Steven Vercauteren, Barbato, Emanuele, Herman, Arnold, Benit, Edouard, Janssens, Luc, Lalmand, Jacque, Hoffer, Etienne, Chenu, Patrick, Guédès, Antoine, Missault, Luc, Pirenne, Bruno, Cardinal, Françoi, Vercauteren, Steven, and Wijns, William

Subjects
Male, Stable angina, Time Factors, Vasodilator Agents, medicine.medical_treatment, Coronary Artery Disease, law.invention, chemistry.chemical_compound, Belgium, Randomized controlled trial, law, Vasodilator Agent, Endothelial dysfunction, Middle Aged, Intercellular Adhesion Molecule-1, Combined Modality Therapy, Reactive hyperemia-peripheral arterial tonometry, Vasodilation, Treatment Outcome, Atherosclerosi, Cardiology, Female, Cardiology and Cardiovascular Medicine, Human, Nitric oxide donor, medicine.medical_specialty, Molsidomine, Time Factor, Manometry, Placebo, Nitric oxide, Percutaneous Coronary Intervention, Double-Blind Method, Internal medicine, medicine, Humans, Nitric Oxide Donors, In patient, Angina, Stable, Aged, Peroxidase, business.industry, Percutaneous coronary intervention, Biomarker, medicine.disease, chemistry, Endothelium, Vascular, business, Biomarkers
Abstract

The MEDCOR trial is a double-blind, randomized study aiming at demonstrating the superiority of molsidomine (direct NO donor) over placebo, used as add-on treatments, on improving endothelial function (EF) after 12 months, in stable angina patients undergoing percutaneous coronary intervention.EF was assessed by peripheral vasodilator response (i.e. Endoscore) using arterial tonometry and by several biomarkers, in terms of changes versus baseline after a one-year treatment.The change in Endoscore was +75 ± 130% in placebo group and +39 ± 145% in molsidomine group (p = 0.143). There was a decrease in sICAM-1 with molsidomine (-6%) and an increase with placebo (+6%). The MPO activity/antigen ratio slightly increased with placebo (+9%) and strongly decreased with molsidomine (-42%) (p = 0.020).The MEDCOR trial was not able to demonstrate significant differences between molsidomine and placebo for all parameters, except the MPO activity/antigen ratio which significantly decreased with molsidomine (p = 0.020 versus placebo).

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results